Aktis Oncology Inc (AKTS)

Aktis Oncology Inc. experienced significant selling activity over the past quarter, with executives offloading shares amid a 34.4% decline in stock price. Notable transactions include planned and proposed divestments by the Chief Medical Officer and other directors. These movements occurred following the August results financiers, as the equity currently trades near its yearly low.
Ticker: AKTS Exchange: NSM


Loading...
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Aktis Oncology Inc. Upgrade to see score, net flow, insiders and the full signal context.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.3
Czibere Akos Chief Medical Officer Officer
Transaction date
Planned sale
Price
69.56
Quantity 98,281 +0.8%
Value US$972,213
3.3
Czibere Akos Chief Medical Officer Officer
Transaction date
Planned sale
Price
358.11
Quantity 17,227 +12.5%
Value US$3,083,138
3.3
Akos Czibere Officer Officer
Transaction date
Proposed sale
Price
305.08
Quantity 20,316
Value US$3,572,896
Herrmann Ken Non-Executive Director
Transaction date
Sale
Price
24.56
Quantity 1,350 -100.0%
Value US$33,159
Herrmann Ken Non-Executive Director
Transaction date
Sale
Price
24.56
Quantity 3,506 -72.2%
Value US$86,115
KEN HERRMANN Director Non-Executive Director
Transaction date
Proposed sale
Price
24.56
Quantity 4,856
Value US$119,275
Herrmann Ken Non-Executive Director
Transaction date
Sale
Price
25.21
Quantity 3,065 -100.0%
Value US$77,259
KEN HERRMANN Director Non-Executive Director
Transaction date
Proposed sale
Price
25.21
Quantity 3,065
Value US$77,259
3.3
Ron-Bigger Shulamit Chief Operating Officer Officer
Transaction date
Sale
Price
28.75
Quantity 4,200 -100.0%
Value US$120,740
3.3
Ron-Bigger Shulamit Chief Operating Officer Officer
Transaction date
Sale
Price
27.94
Quantity 30,000 -87.7%
Value US$838,137
3.3
Ron-Bigger Shulamit Chief Operating Officer Officer
Transaction date
Sale
Price
27.13
Quantity 15,800 -31.6%
Value US$428,681
3.3
Czibere Akos Chief Medical Officer Officer
Transaction date
Sale
Price
28.71
Quantity 4,371 -100.0%
Value US$125,482
3.3
Czibere Akos Chief Medical Officer Officer
Transaction date
Sale
Price
27.95
Quantity 30,829 -87.6%
Value US$861,735
3.3
Czibere Akos Chief Medical Officer Officer
Transaction date
Sale
Price
27.13
Quantity 14,800 -29.6%
Value US$401,484
3.3
AKOS CZIBERE Officer Officer
Transaction date
Proposed sale
Price
27.77
Quantity 50,000
Value US$1,388,700
3.3
SHULAMIT RON-BIGGER Officer Officer
Transaction date
Proposed sale
Price
27.75
Quantity 50,000
Value US$1,387,560
2.8
Foley Todd Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 232,870 +5.8%
Value US$4,191,660
3.1
GADICKE ANSBERT Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 1,112,777 +12.2%
Value US$20,029,986
3.1
EcoR1 Capital, LLC Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 144,443 +71.2%
Value US$2,599,974
3.1
EcoR1 Capital, LLC Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 2,077,779 +91.5%
Value US$37,400,022
Vida Ventures II, LLC Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 22,545 +16.7%
Value US$405,810
Vida Ventures II, LLC Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 812,455 +16.7%
Value US$14,624,190
Kim Helen Susan Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 22,545 +16.7%
Value US$405,810
Kim Helen Susan Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 812,455 +16.7%
Value US$14,624,190
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2026-09-24 2026-09-23 PlS Planned sale

Chief Medical Officer

Officer
98,281 +0.8%
69.56
US$972,213
98,281 +0.8% 69.56 US$972,213
2026-09-24 2026-09-23 PlS Planned sale

Chief Medical Officer

Officer
17,227 +12.5%
358.11
US$3,083,138
17,227 +12.5% 358.11 US$3,083,138
2026-09-23 2026-09-23 PrS Proposed sale

Officer

Officer
20,316
305.08
US$3,572,896
20,316 305.08 US$3,572,896
2026-07-21 2026-07-20 S Sale Non-Executive Director
1,350 -100.0%
24.56
US$33,159
1,350 -100.0% 24.56 US$33,159
2026-07-21 2026-07-20 S Sale Non-Executive Director
3,506 -72.2%
24.56
US$86,115
3,506 -72.2% 24.56 US$86,115
2026-07-20 2026-07-20 PrS Proposed sale

Director

Non-Executive Director
4,856
24.56
US$119,275
4,856 24.56 US$119,275
2026-07-20 2026-07-17 S Sale Non-Executive Director
3,065 -100.0%
25.21
US$77,259
3,065 -100.0% 25.21 US$77,259
2026-07-17 2026-07-17 PrS Proposed sale

Director

Non-Executive Director
3,065
25.21
US$77,259
3,065 25.21 US$77,259
2026-07-10 2026-07-08 S Sale

Chief Operating Officer

Officer
4,200 -100.0%
28.75
US$120,740
4,200 -100.0% 28.75 US$120,740
2026-07-10 2026-07-08 S Sale

Chief Operating Officer

Officer
30,000 -87.7%
27.94
US$838,137
30,000 -87.7% 27.94 US$838,137
2026-07-10 2026-07-08 S Sale

Chief Operating Officer

Officer
15,800 -31.6%
27.13
US$428,681
15,800 -31.6% 27.13 US$428,681
2026-07-10 2026-07-08 S Sale

Chief Medical Officer

Officer
4,371 -100.0%
28.71
US$125,482
4,371 -100.0% 28.71 US$125,482
2026-07-10 2026-07-08 S Sale

Chief Medical Officer

Officer
30,829 -87.6%
27.95
US$861,735
30,829 -87.6% 27.95 US$861,735
2026-07-10 2026-07-08 S Sale

Chief Medical Officer

Officer
14,800 -29.6%
27.13
US$401,484
14,800 -29.6% 27.13 US$401,484
2026-07-08 2026-07-08 PrS Proposed sale

Officer

Officer
50,000
27.77
US$1,388,700
50,000 27.77 US$1,388,700
2026-07-08 2026-07-08 PrS Proposed sale

Officer

Officer
50,000
27.75
US$1,387,560
50,000 27.75 US$1,387,560
2026-01-14 2026-01-12 B Purchase Non-Executive Director Large shareholder
232,870 +5.8%
18.00
US$4,191,660
232,870 +5.8% 18.00 US$4,191,660
2026-01-14 2026-01-12 B Purchase Large shareholder
1,112,777 +12.2%
18.00
US$20,029,986
1,112,777 +12.2% 18.00 US$20,029,986
2026-01-14 2026-01-12 B Purchase Large shareholder
1,112,777 +12.2%
18.00
US$20,029,986
1,112,777 +12.2% 18.00 US$20,029,986
2026-01-12 2026-01-12 B Purchase Non-Executive Director
144,443 +71.2%
18.00
US$2,599,974
144,443 +71.2% 18.00 US$2,599,974
2026-01-12 2026-01-12 B Purchase Non-Executive Director
2,077,779 +91.5%
18.00
US$37,400,022
2,077,779 +91.5% 18.00 US$37,400,022
2026-01-12 2026-01-12 B Purchase Large shareholder
22,545 +16.7%
18.00
US$405,810
22,545 +16.7% 18.00 US$405,810
2026-01-12 2026-01-12 B Purchase Large shareholder
812,455 +16.7%
18.00
US$14,624,190
812,455 +16.7% 18.00 US$14,624,190
2026-01-12 2026-01-12 B Purchase Non-Executive Director Large shareholder
22,545 +16.7%
18.00
US$405,810
22,545 +16.7% 18.00 US$405,810
2026-01-12 2026-01-12 B Purchase Non-Executive Director Large shareholder
812,455 +16.7%
18.00
US$14,624,190
812,455 +16.7% 18.00 US$14,624,190